Gloria Pascual receives a prize for her research into the relation between fats and metastasis
The Pfizer Foundation has awarded the IRB Barcelona scientist a prize within the “Basic Research” category.
Gloria Pascual, a member of the Stem Cells and Cancer lab, will receive €10,000 to continue her research
Gloria Pacual, associate researcher at the Institute for Research in Biomedicine (IRB Barcelona), has been awarded a Scientific Innovation Prize from the Pfizer Foundation, within the “Basic Research” category. Her work ‘Targeting metastasis-initiating cells through the fatty acid receptor CD36’ paves the way to tackle various kinds of metastatic cancer.
Published in the journal Nature and headed by IRB Barcelona’s Stem Cells and Cancer lab, the study has identified a subpopulation of cells that are responsible for the development of metastasis. The main conclusion drawn from the work is that only cancer cells that express the protein CD36 on their surface have the capacity to colonize and grow in other organs.
“This protein is a fatty acid receptor, and we have discovered that, during metastasis, cells that have this molecule use lipids from their microenvironment, thus conferring them the capacity to migrate to and grow in distant organs,” explains the scientist.
Thanks to this discovery, the researchers have been able to use monoclonal antibodies that target CD36, obtaining good results in animals. “Using this anti-CD36 treatment, we have been able to inhibit the onset of metastasis in mice with a primary tumour but that have not yet developed metastasis,” concludes Gloria Pascual.
Acknowledgement of scientific progress
This year’s awards, each worth €10,000, mark the 20th year in which the Pfizer Foundation has acknowledged scientific progress in the fields of life sciences in the categories “Basic Research” and “Clinical Research”. The other prize was given to Belén Gutiérrez-Gutiérrez, from the Hospital Virgen Macarena in Seville, for her work on multi-resistant bacteria.
Both scientists received their prizes yesterday in a presentation ceremony held in Madrid.
Related content
News
The mechanism unveiled triggers a mutation fog, causing hundreds of mutations in each tumor, which spread through the genome of lung, head-and-neck and breast cancers.
Researchers from the Genome Data Science Lab have identified the antiviral APOBEC3A enzyme as the major cause of this new type of hypermutation.
Published in Nature Genetics, the study shows how the mutation fog process generates many oncogenic “cancer driver” mutations, thus accelerating tumour development.
To mark World Cancer Day, the programme El Matí de Barcelona Betevé broadcasted by Radio Barcelona has interviewed Roger Gomis, ICREA Researcher and head of the Growth Control and Metastasis Lab at IRB Barcelona. During the interview, he talked about metastasis, the process by which a tumour spreads to the rest of the body, allowing cancer cells to adapt to new environments “What we are focusing on in our lab is precisely how this cell adaptation and plasticity comes about,” says Gomis.
The “Preguntas Big Van” section of the newspaper La Vanguardia interviewed Eduard Batlle, ICREA researcher and head of the Colorectal Cancer Lab at IRB Barcelona, about his collaboration with the Centro de Análisis Genómico regarding the study of colorectal tumour samples using the new unicellular analysis method. “This technique allows us to see what is happening inside the tumour at a level of detail that was unimaginable 5 years ago,” says Batlle.
- Trustees:
-
- Center:
- A member of:
- Recognised by:
